Incyte (NASDAQ:INCY – Get Free Report) and Organogenesis (NASDAQ:ORGO – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, profitability, risk, earnings and dividends.
Volatility & Risk
Incyte has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.
Insider & Institutional Ownership
97.0% of Incyte shares are held by institutional investors. Comparatively, 49.6% of Organogenesis shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 18.8% of Organogenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Incyte and Organogenesis”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Incyte | $5.14 billion | 4.57 | $1.29 billion | $1.88 | 61.32 |
| Organogenesis | $564.17 million | 0.19 | $37.03 million | ($1.22) | -0.66 |
Incyte has higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Incyte and Organogenesis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Incyte | 6.71% | 7.92% | 6.12% |
| Organogenesis | -39.34% | -55.28% | -23.72% |
Analyst Ratings
This is a summary of current ratings and price targets for Incyte and Organogenesis, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Incyte | 0 | 14 | 11 | 0 | 2.44 |
| Organogenesis | 1 | 2 | 0 | 0 | 1.67 |
Incyte currently has a consensus target price of $133.86, suggesting a potential upside of 16.11%. Organogenesis has a consensus target price of $4.33, suggesting a potential upside of 438.30%. Given Organogenesis’ higher possible upside, analysts plainly believe Organogenesis is more favorable than Incyte.
Summary
Incyte beats Organogenesis on 11 of the 14 factors compared between the two stocks.
About Incyte
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
About Organogenesis
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
